Biocon Limited — Q4 FY24
Biocon's Q4 FY24 group revenue from operations grew 4% YoY to INR 3,917 crore, with core EBITDA margin of 30%.
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
46%Questions answered3Evaded / deflected12Questions audited
Partial answer
High priority
Growth headroom and trajectory for commercial biosimilars in U.S.
Asked by Damayanti Kerai, HSBC
Acknowledged momentum but gave no quantitative growth trajectory or headroom specifics.
no specific growth rate givendeferred to FY26
Read the exchange
Question
Just want to understand, in the commercial biosimilars, what kind of further headroom you see for growth and how should we see this biosimilar growth trajectory from $1 billion mark?
Peter Bains, CEO
We're seeing some very robust market share increases... sustained demand in volume... new product launches... the major impact would be seen in fiscal 2026.
Partial answer
High priority
Progress on market access and payer coverage for adalimumab.
Asked by Damayanti Kerai, HSBC
Provided timeline but no concrete progress metrics on payer coverage.
no specific payer coverage detailsdeferred to 2025
Read the exchange
Question
My second question is on your progress in efforts to gain market access and payer coverage for adalimumab... maybe you can just update us on your effort on the payer coverage side.
Peter Bains, CEO; Matthew Erick, EVP
We don't really see the market opening up in calendar 2024, but we'll see it begin to open up more materially in 2025... we are aggressively pursuing these opportunities.
Answered
High priority
Will Biocon be in first wave of denosumab launches?
Asked by Jainil Shah, JM Financial
Confirmed first wave status with specific filing timeline.
Read the exchange
Question
Sandoz has settled with the innovator... do you believe that we will be in the first wave of launches? Because we'll be filing by the end of this year.
Sandeep Athalye, Chief Development Officer
We are in a good position to make the filings in the next few months, and we'll be the first cohort that can launch in the U.S. and Europe as well.
Answered
Medium priority
Timelines for denosumab and Stelara approvals and risks.
Asked by Jainil Shah, JM Financial
Provided standard regulatory timelines without specific risks.
Read the exchange
Question
Any timelines for approval for both denosumab, Stelara, and any risks that you see to those timelines?
Sandeep Athalye, Chief Development Officer
Regular cycle is about 12 months for the FDA and about 15 months with the clock stop for EMA. So that will be standard as expected for all the molecules.
Partial answer
Medium priority
CapEx plans for next 2-3 years.
Asked by Jainil Shah, JM Financial
Qualitative direction but no quantitative CapEx guidance.
no specific numbers given
Read the exchange
Question
Just one on the CapEx that we are planning for the next 2-3 years.
Peter Bains, CEO
CapEx will taper down, calibrate down from recent levels, but we will be maintaining the necessary investments to support the capacities...
Evasive
High priority
Growth guidance and number of launches in generics business.
Asked by Jainil Shah, JM Financial
Declined to provide specific numbers or guidance.
no growth guidanceno launch count
Read the exchange
Question
In the generics business, what's our growth guidance, and how many launches do we expect next year?
Siddharth Mittal, CEO
I cannot give you exact number of products, but needless to say, our portfolio continues to be limited... these are differentiated, high-value products.
Evasive
High priority
Revenue growth outlook for biosimilars in FY25 given price competition.
Asked by Surya Patra, Phillip Capital
Did not provide a growth estimate; challenged the premise.
no growth numbercorrected premisedeferred to FY26
Read the exchange
Question
What growth one should really think for the biosimilars portfolio in FY 2025?
Peter Bains, CEO; Shreehas Tambe, CEO & MD
We would expect that growth momentum to continue during fiscal 2024... I don't quite see the market starting point as you describe.
Partial answer
High priority
Is Humira losing share to other biosimilars, shrinking opportunity?
Asked by Surya Patra, Phillip Capital
Explained market dynamics but did not directly address if opportunity is shrinking.
no direct answer on shrinking opportunity
Read the exchange
Question
Humira has seen some kind of a revenue decline... whether biosimilar opportunity is likely to be believed to be shrinking for adalimumab?
Shreehas Tambe, CEO & Managing Director
2023 essentially was where the innovator continued to hold more than 98% of the market... meaningful progress on the biosimilars will only happen in 2025.
Partial answer
Medium priority
Status of marketing arrangement with Viatris and R&D spend run rate.
Asked by Surya Patra, Phillip Capital
Confirmed marketing arrangement ended but gave no R&D run rate number.
no specific R&D spend guidance
Read the exchange
Question
Whether that marketing arrangement is effective for FY 25... And secondly, about R&D spend... whether it is the kind of fair run rate that one should build for next year?
Peter Bains, CEO
The marketing arrangements with Viatris have now all successfully completed... there are no marketing arrangements left... R&D... calibration down from previous levels.
Partial answer
High priority
Risk to Biocon's Humira share from private label launches gaining traction.
Asked by Neha Manpuria, Bank of America
Acknowledged risk but gave no specifics on share expectations.
no market share targetno quantification of risk
Read the exchange
Question
Does that put our ability to then get in and get meaningful share at risk, with these existing players probably scaling up?
Matthew Erick, EVP
That does not leave all the market out for Biocon. The market is open in the commercial, in the Medicare, in the Medicaid business.
Evasive
High priority
Net debt reduction plan and avenues for Biocon and BBL in next year.
Asked by Neha Manpuria, Bank of America
Listed options but refused to give any numbers or commitments.
no quantitative guidanceno timeline
Read the exchange
Question
How should we think about net debt reduction for BBL and Biocon, in the next year? I mean, what avenues are we looking at to reduce debt?
Peter Bains, CEO
We have bank opportunities, we have equity opportunities, we have hybrid opportunities... I can't give any specific quantitative guidance on that.
Partial answer
High priority
Status of GLP-1 approval in U.S. market.
Asked by Nitin Agarwal, DAM Capital
Provided status but no expected approval date.
no specific approval timeline
Read the exchange
Question
Where are we on the approval for GLP-1 in the U.S. market?
Siddharth Mittal, CEO
The file is under review with the FDA... we expect liraglutide to meaningfully start contributing to the growth from FY 2026.